BI

BioRock Ventures — Seed & Series A VC Firm

VC

BioRock Ventures is a Seed, Series A venture capital firm investing in Healthcare. The firm has 7 portfolio companies in our records.

Portfolio
7 companies on record
Partners
1 listed
Stage
Seed, Series A
Sectors
Healthcare
Check size
Not in our records
AUM
Not in our records

Last verified: 2026-10-27

How to approach: warm intro preferred
Stage

Seed, Series A

Portfolio

7+ companies

Team

1 partner

Investment Thesis

Seed VC fund investing in startups developing best-in-class medicines and novel FDA-regulated therapeutic drugs. The firm explicitly backs private life science companies across angel, seed, Series A, and later stages.

How BioRock Ventures invests

BioRock Ventures is a vc firm. The firm invests at the Seed, Series A stages, with a focus on Healthcare.

BioRock Ventures has backed 7 companies in our records, including Immusoft, Vidya Therapeutics, AN2.

Partners & Team

MW

Mary Wheeler

Managing Director

therapeutics startups
M&A
licensing deals

Mary is founding managing partner of BioRock Ventures in the Bay Area, CA. Mary began two decades of operating experience as a therapeutics startup founder in Boston. She moved to roles leading negotiations, business and technical evaluations for M&A and licensing deals as well as strategy roles at large and medium pharmaceuticals companies like Johnson & Johnson and Forest, now Allergan/Abbvie, in NYC. She also has served as consulting CBO for several dozen early stage ventures around the world. She began venture investing a decade ago where she helped form and put first money into two new companies which each had IPO exits valued over $1 Billion. Mary is a Kauffman Fellow, earned an MBA from MIT Sloan, a PhD from Princeton University and an undergraduate degree from Yale University.

Industry Focus

Invests In

Healthcare

Portfolio Companies (7)

Other

IM

Immusoft

Fund II

Develops engineered B cell therapies to produce therapeutic proteins in patients

VI

Vidya Therapeutics

Fund II

Exit, acquired

AN

AN2

PR

Primmune Therapeutics

Fund I

Develops immune-system-based therapies

PT

PTM Therapeutics, Inc.

Fund I

Therapeutics company

VA

Vaxcyte

Develops broad-spectrum vaccines

AN

AN2 Therapeutics

biotech / small-molecule drug development·not specified·Fund I

Develops small-molecule therapeutics from a boron chemistry platform

How to pitch BioRock Ventures
  • •Raising at Seed, Series A? You're squarely in their sweet spot.
  • •Lead with your fit in Healthcare — the sectors they actively back.
  • •warm intro preferred
  • •Address your outreach to a specific partner, such as Mary Wheeler, Managing Director.
  • •A warm introduction beats a cold email. Get matched and request an intro.

Featured In

Browse More Investors

Fundraising resources

Frequently Asked Questions

See if BioRock Ventures is a match for your startup

Upload your pitch deck to see how well you match with BioRock Ventures and 10,000+ other investors.

Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT

Is this your profile? Request a correction or removal